Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations

Core Viewpoint - Palvella Therapeutics has launched the "BEYOND mLM" campaign to raise awareness and educate about microcystic lymphatic malformations (microcystic LMs), a rare disease affecting over 30,000 patients in the U.S. with no FDA-approved therapies available [1][7]. Company Overview - Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases and vascular malformations, with a lead product candidate, QTORIN™ rapamycin, aimed at treating microcystic LMs [8][9]. - The company is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, targeting conditions that currently lack FDA-approved treatments [8]. Disease Background - Microcystic LMs are characterized by malformed lymphatic vessels that can leak lymph fluid and bleed, leading to recurrent infections and hospitalizations [2][7]. - The disease is chronic and progressive, often presenting in childhood, with no spontaneous resolution, resulting in increased morbidity over time [7]. Campaign Details - The "BEYOND mLM" campaign is developed in collaboration with leading nonprofit organizations to provide educational resources for patients, caregivers, and healthcare professionals [1][4]. - The campaign aims to improve understanding of microcystic LMs, facilitate care navigation, and foster community connections through patient stories and expert insights [4][6]. Collaborative Partners - The campaign involves partnerships with organizations such as the Consortium of iNvestigators of Vascular AnomalieS (CaNVAS), Lymphangiomatosis & Gorham's Disease Alliance (LGDA), and others, bringing expertise and advocacy to improve patient outcomes [3][5].